Evidence map›Paper›PMID 39789858›Full record

ArticleThe Journal of infectious diseases2025

Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis.

A Stoltz, R R Nathavitharana, E de Kock, V Ueckermann, P Jensen, C M Mendel, M Spigelman, E A Nardell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A StoltzDepartment of Infectious Diseases, University of Pretoria School of Medicine, Pretoria, South Africa.
R R NathavitharanaDivision of Infectious Diseases, Beth Israel Deaconess Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-3544-5021
E de KockRetrasol, Pretoria, South Africa.ORCID 0009-0007-3161-1540
V UeckermannDepartment of Infectious Diseases, University of Pretoria School of Medicine, Pretoria, South Africa.ORCID 0000-0002-4419-3583
P JensenDivision of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
C M MendelGlobal Alliance for TB Drug Development, New York, New York, USA.
M SpigelmanGlobal Alliance for TB Drug Development, New York, New York, USA.
E A NardellDivision of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-5323-3196

Funding

Optimizing Diagnostic Strategies for TB Transmission Control in Health-Care FacilitiesK23AI132648 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI NATHAVITHARANA, RUVANDHI · 2018 to 2022
$945k
Impact of Effective Chemotherapy on Transmission of Drug Resistant TuberculosisR01AI099603 · NIAID · UNIVERSITY OF PRETORIA · PI STOLTZ, ANTON CAREL · 2012 to 2016
$781k
National Institute of Allergy and Infectious Diseases K23 AI132648-05NIAID NIH HHS K23 AI132648NIAID NIH HHS R01 AI099603NIH HHS 5R01AI099603-05
6 · The paper itself

Abstract

backgroundMost drug-resistant tuberculosis occurs due to transmission of unsuspected or ineffectively treated drug-resistant tuberculosis. The duration of treatment to stop person-to-person spread of drug-resistant tuberculosis is uncertain. We evaluated the impact of novel regimens, including BPaL (bedaquiline, 1200-mg linezolid, and pretomanid), on drug-resistant tuberculosis transmission, using the human-guinea pig (H-GP) transmission model.

methodsIn experiment 1, patients initiated an optimized drug-resistant tuberculosis regimen including bedaquiline and linezolid. In experiment 2, patients initiated the BPaL regimen. We measured baseline infectivity for each cohort by exhausting ward air to one of two guinea pig exposure rooms (control group), each containing 90 guinea pigs, for 8 patient-days. Then, after 72 hours of treatment, ward air was exhausted to the second guinea pig exposure room for 8 patient-days (intervention group). The infectiousness of each cohort was compared by performing tuberculin skin tests in guinea pigs at baseline (before treatment) and 6 weeks after the exposure period.

resultsIn experiment 1, before treatment, 5 patients with drug-resistant tuberculosis infected 24 of 90 guinea pigs (26.7%) (control group). After treatment (72 hours after drug initiation), the same patients infected 25 of 90 guinea pigs (27.8%) (intervention group) (P > .99). In experiment 2, before treatment, 9 patients with drug-resistant tuberculosis infected 40 of 90 guinea pigs (44.4%) (control group). After treatment (beginning 72 hours after drug initiation), the same patients infected 0 of 90 guinea pigs (0%) (intervention group) (P < .0001).

conclusionsIn this study, drug-resistant tuberculosis drug regimens, including bedaquiline and standard-dose linezolid for 72 hours, did not decrease drug-resistant tuberculosis transmission. In contrast, transmission was rapidly and completely inhibited in patients treated with BPaL for 72 hours, suggesting an early and profound impact on transmission.

Indexed as

Antitubercular AgentsTuberculosis, Multidrug-ResistantAdultAnimalsDiarylquinolinesFemaleGuinea PigsHumansLinezolidMaleMiddle AgedMycobacterium tuberculosisNitroimidazolesTuberculin TestAntitubercular AgentsbedaquilineDiarylquinolinesLinezolidNitroimidazolespretomaniddrug-resistant tuberculosisearly transmission impacttransmissiontuberculosistuberculosis treatment

Identifiers

PMID39789858
PMCPMC12308646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.